|
|
Pathways for Optimal Sequencing, Rapid Initiation, and Titration of Therapy in Patients with Heart Failure
Many patients with heart failure (HF) do not receive foundational treatment although these therapies reduce morbidity and mortality risks. The initiation and optimization of guideline-directed medical therapies (GDMT) can be challenging, but clinical practice guidelines and algorithms are available to assist.
Navigate through this interactive self-directed CME activity to apply the most recent clinical trial data and guidance to patient-specific factors seen in real-world practice. Expert p... |
|
|
Multidisciplinary Strategies to Prevent Hospitalization in Patients with Worsening Heart Failure
Despite guideline-directed medical therapy, many patients with heart failure (HF) with reduced ejection fraction continue to experience worsening HF and hospitalizations. As such, it is incumbent upon clinicians to improve familiarity and competence with available therapies and clinical trial data that may guide patient selection to individualize and optimize therapy for patients with HF. In this interactive infographic, clinicians can access real-world strategies and expert insights to improv... |
|
|
Clinical Questions in Cardiology: Using Glucagon-like Peptite-1 Receptor Agonists
The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications has become an important option for treating patients with type 2 diabetes mellitus (T2D). Cardiovascular outcome trials also show that selected GLP-1RAs exert beneficial cardiovascular benefits in patients with and without T2D. In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and th... |
|
|
WEBINAR: Legal Insights into Peptide & Semaglutide Compounding: Navigating FDA, State Boards, and Telemedicine
As the landscape of compounding peptides and semaglutide continues to evolve rapidly, a multitude of legal challenges and opportunities arise. This session aims to shed light on the pivotal developments and regulatory nuances in this dynamic sector.
Our speakers will delve into critical topics such as the FDA's current stance on peptide compounding, recent pronouncements from state Boards of Pharmacy, and the intricate legalities surrounding brand manufacturers. Additionally, the webi... |
|